Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (320)

« Back to Publications

Glucocorticoid Prescribing Trends in Congenital Adrenal Hyperplasia, 2017 to 2023.

Roxas A. et al, (2026), Endocr Connect

Sleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non-Diabetic Hyperglycaemia.

Sharman R. et al, (2026), J Sleep Res

biological-systems-based analysis using proteomic and metabolic network inference reveals mechanistic insights into hepatic steatosis.

Atabaki NN. et al, (2026), Metabolism

Clinical features, investigation, and management of Addison's disease.

Dong J. et al, (2026), Lancet Diabetes Endocrinol

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.

Marjot T. et al, (2026), Cell Metab

The Impact of Estrogen Deficiency on Liver Metabolism: Implications for Hormone Replacement Therapy.

Dong J. et al, (2025), Endocr Rev, 46, 790 - 809

Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.

Liu J. et al, (2025), J Hepatol, 83, 1035 - 1045

Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries.

Younossi ZM. et al, (2025), Clin Gastroenterol Hepatol

Dose-dependent and tissue-specific adverse effects of exogenous glucocorticoids: insights for optimizing clinical practice.

Pofi R. et al, (2025), J Endocrinol Invest, 48, 2067 - 2076

Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?

Dissanayake HA. et al, (2025), Clin Endocrinol (Oxf), 103, 129 - 136

Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.

de Bray A. et al, (2025), Nat Metab, 7, 1536 - 1549

Pregnancy Outcomes in Women With Primary Adrenal Insufficiency: Data From a Multicentre Cohort Study.

Cauldwell M. et al, (2025), BJOG, 132, 1122 - 1129

Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?

Tomlinson JW., (2025), J Clin Invest, 135

Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.

Koutoukidis DA. et al, (2025), J Cachexia Sarcopenia Muscle, 16

Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD.

Moolla A. et al, (2025), JHEP Rep, 7

Load More

1
2
3
4
5
6
7
...
»